Advanced Oncotherapy Management
Management criteria checks 2/4
Advanced Oncotherapy's CEO is Nicolas Serandour, appointed in Oct 2016, has a tenure of 7.08 years. directly owns 0.4% of the company’s shares, worth £38.10K. The average tenure of the management team and the board of directors is 8.3 years and 8.6 years respectively.
Key information
Nicolas Serandour
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 7.1yrs |
CEO ownership | 0.4% |
Management average tenure | 8.3yrs |
Board average tenure | 8.6yrs |
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2022 | n/a | n/a | -UK£33m |
Mar 31 2022 | n/a | n/a | -UK£31m |
Dec 31 2021 | UK£503k | UK£300k | -UK£29m |
Sep 30 2021 | n/a | n/a | -UK£28m |
Jun 30 2021 | n/a | n/a | -UK£26m |
Mar 31 2021 | n/a | n/a | -UK£26m |
Dec 31 2020 | UK£336k | UK£300k | -UK£25m |
Sep 30 2020 | n/a | n/a | -UK£24m |
Jun 30 2020 | n/a | n/a | -UK£22m |
Mar 31 2020 | n/a | n/a | -UK£21m |
Dec 31 2019 | UK£401k | UK£247k | -UK£21m |
Sep 30 2019 | n/a | n/a | -UK£21m |
Jun 30 2019 | n/a | n/a | -UK£21m |
Mar 31 2019 | n/a | n/a | -UK£21m |
Dec 31 2018 | UK£1m | UK£233k | -UK£21m |
Jun 30 2018 | n/a | n/a | -UK£18m |
Mar 31 2018 | n/a | n/a | -UK£16m |
Dec 31 2017 | UK£239k | UK£215k | -UK£14m |
Jun 30 2017 | n/a | n/a | -UK£12m |
Mar 31 2017 | n/a | n/a | -UK£11m |
Dec 31 2016 | UK£208k | UK£180k | -UK£10m |
Compensation vs Market: Insufficient data to establish whether Nicolas's total compensation is reasonable compared to companies of similar size in the UK market.
Compensation vs Earnings: Nicolas's compensation has increased whilst the company is unprofitable.
CEO
Nicolas Serandour (48 yo)
7.1yrs
Tenure
UK£502,965
Compensation
Mr. Nicolas Serandour has been the Chief Executive Officer of Advanced Oncotherapy Plc since October 27, 2016. Mr. Serandour served as the Chief Financial Officer and Chief Operating Officer at Advanced On...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 17.4yrs | UK£434.42k | 1.74% £ 165.2k | |
CEO & Executive Director | 7.1yrs | UK£502.97k | 0.40% £ 38.1k | |
Executive Director | no data | UK£397.72k | 0.28% £ 27.0k | |
COO & President of Europe | 6.4yrs | no data | no data | |
Senior Vice-President of Accounting | 10.9yrs | no data | no data | |
Senior Vice-President of Corporate Finance | no data | no data | no data | |
Director of Technical & Engineering | no data | no data | no data | |
Vice President of Investor and Public Relations | 6.9yrs | no data | no data | |
Director of Human Resources | 7yrs | no data | no data | |
Managing Director of ADAM | 15.4yrs | no data | no data | |
Head of Physics Group | 10.2yrs | no data | no data | |
Head of Radiofrequency Group | 9.6yrs | no data | no data |
8.3yrs
Average Tenure
76yo
Average Age
Experienced Management: AVO's management team is seasoned and experienced (8.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 17.4yrs | UK£434.42k | 1.74% £ 165.2k | |
CEO & Executive Director | 9.3yrs | UK£502.97k | 0.40% £ 38.1k | |
Executive Director | 8yrs | UK£397.72k | 0.28% £ 27.0k | |
Member of Medical Advisory Board | 5.8yrs | UK£15.00k | no data | |
Senior Independent Director | 6.8yrs | UK£67.50k | 0.18% £ 17.2k | |
Member of Medical Advisory Board | 10.1yrs | no data | no data | |
Independent Non-Executive Director | 10.1yrs | UK£62.50k | 0.75% £ 71.3k | |
Member of Medical Advisory Board | no data | no data | no data | |
Independent Non-Executive Director | 10.6yrs | UK£50.00k | 1.54% £ 146.2k | |
Independent Chairman of Medical Advisory Board & Non-Executive Director | 6.8yrs | UK£40.00k | 0.86% £ 81.8k | |
Member of Medical Advisory Board | no data | no data | no data | |
Independent Non-Executive Director | 5.3yrs | UK£30.00k | no data |
8.6yrs
Average Tenure
73yo
Average Age
Experienced Board: AVO's board of directors are considered experienced (8.6 years average tenure).